News

CDC recommends value-based strategies to help members control high blood pressure

The Medicare Part D prescription drug program has emerged as the poster child for how private plans can control costs while providing quality care. Even critics of health insurers acknowledge that the drug benefit has been a success.

Drug Watch: Pain

Recent FDA action (through August 2012) related to, ferric carboxymaltose injection, Injectafer, abiraterone acetate, Zytiga, cabozantinib, Exelixis, eltrombopag, Promacta, AEZS-130 oral ghrelin agonist, inhaled nitric oxide, GeNO LLC, gevokizumab, XOMA, calcipotriene cream, Dovonex, montelukast sodium, Singulair, lidocaine topical patch 5%, Lidoderm, filgrastim, Neupogen

New molecular entity: FDA approved Mirabegron (Myrbetriq, Astellas Pharma US) for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Irritable bowel syndrome is functional gastrointestinal disorder that is expensive to treat and can impair quality of life. Current therapies are reviewed.

A look at the decision process that lead the Mayo Clinic to abandon the 80-mg dose of simvastatin

A recent study indicates that patients taking statins have a higher risk of developing cataracts.

Recent FDA Approvals (through August 2012) related to (CSL Limited, GlaxoSmithKline Biologicals, ID Biomedical Corp, MedImmune Vaccines, Novartis Vaccines and Diagnostics Limited, Sanofi Pasteur, Genentech, Talon Therapeutics, Amarin, Regeneron Pharmaceuticals, Horizon Pharma, Forest Pharmaceuticals, Onyx Pharmaceuticals, Novartis, Pfizer, Sagent Pharmaceuticals)

New molecular entity: FDA approved Lorcaserin (Belviq, Arena Pharmaceuticals GMBH), as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index deemed obese and the presence of at least 1 weight-related comorbid condition.

A significant number of men who developed persistent sexual side effects from taking finasteride (Propecia and Proscar) also suffer from depressive symptoms and suicidal thoughts, according to a study published online in the Journal of Clinical Psychiatry.

Incretin-based therapies are now the most promising therapies for type 2 diabetes.

Teduglutide is a recombinant analog of human glucagon-like peptide-2 that is awaiting FDA approval for the treatment of short bowel syndrome (SBS) as a once-daily subcutaneous injection.

Real-time data sharing plays big role in effective, high-quality care.

Reduction in uncompensated care benefits insurers

Integrating mental health and behavioral health unlocks a value proposition

As the industry moves toward a retail environment, the importance of becoming member-centric can't be understated.

Symptoms of insomnia can be treated with several different drugs, but be aware of side effects.

Some hospitals are feeling the pinch of the Great Recession.

With implant-device costs on the rise, encourage members to seek preferred sites of care.

Paul B. Ginsburg discusses how new payment models are progressing

Lower courts will decide on the lingering concerns of uncertain PPACA provisions.

Early efforts by states drive value with Medicaid ACOs, coordinated care.

Ryan's proposals for radical changes in Medicare and Medicaid are at the center of the presidential campaign.

A recent study underscores the intuitive fact that a small percentage of patients consume a disproportionate share of healthcare dollars.

Watch healthcare spending shift and increase over the last 50 years.

FDA approved enzalutamide (Xtandi, Astellas Pharma U.S. Inc. and Medivation) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.

FDA issued a Drug Safety Communication on sildenafil (Revatio, Pfizer), following the observation in a long-term extension of a clinical trial in pediatric patients with pulmonary arterial hypertension of an increase in mortality with increasing Revatio dose.

Missouri study indicates LGBT discrimination and poorer health outcomes

Children with cystic fibrosis who are taking ivacaftor (Kalydeco) may be at potential risk for cataracts, according to an FDA notification.